Associated Banc Corp reduced its position in shares of Roche Holdings AG Basel ADR (OTCMKTS:RHHBY) by 3.3% in the 3rd quarter, Holdings Channel reports. The firm owned 64,798 shares of the company’s stock after selling 2,183 shares during the quarter. Associated Banc Corp’s holdings in Roche Holdings AG Basel were worth $1,971,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the business. Cornerstone Investment Partners LLC bought a new stake in shares of Roche Holdings AG Basel in the 3rd quarter valued at about $206,000. Mechanics Bank Trust Department bought a new stake in shares of Roche Holdings AG Basel in the 3rd quarter valued at about $207,000. Dearborn Partners LLC bought a new stake in shares of Roche Holdings AG Basel in the 3rd quarter valued at about $232,000. Gardiner Nancy B bought a new stake in shares of Roche Holdings AG Basel in the 3rd quarter valued at about $454,000. Finally, Advisor Partners LLC increased its stake in shares of Roche Holdings AG Basel by 77.1% in the 3rd quarter. Advisor Partners LLC now owns 23,100 shares of the company’s stock valued at $703,000 after acquiring an additional 10,053 shares during the last quarter. 0.31% of the stock is owned by hedge funds and other institutional investors.

Shares of RHHBY opened at $31.10 on Wednesday. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.28 and a quick ratio of 0.97. Roche Holdings AG Basel ADR has a 52-week low of $26.30 and a 52-week high of $32.42. The company has a market capitalization of $213.29 billion, a P/E ratio of 15.95, a price-to-earnings-growth ratio of 1.89 and a beta of 0.53.

Several equities analysts recently issued reports on the company. ValuEngine upgraded Roche Holdings AG Basel from a “sell” rating to a “hold” rating in a research report on Thursday, August 30th. Zacks Investment Research upgraded Roche Holdings AG Basel from a “hold” rating to a “strong-buy” rating and set a $35.00 price objective for the company in a research report on Wednesday, September 12th. Wolfe Research assumed coverage on Roche Holdings AG Basel in a research report on Tuesday, October 23rd. They issued a “market perform” rating for the company. Cowen reiterated a “buy” rating and issued a $34.00 price objective on shares of Roche Holdings AG Basel in a research report on Thursday, July 26th. Finally, Bank of America lowered Roche Holdings AG Basel from a “buy” rating to a “neutral” rating in a research report on Monday, September 10th. Three research analysts have rated the stock with a sell rating, four have issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $34.50.

COPYRIGHT VIOLATION NOTICE: “Associated Banc Corp Sells 2,183 Shares of Roche Holdings AG Basel ADR (RHHBY)” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2018/11/14/associated-banc-corp-sells-2183-shares-of-roche-holdings-ag-basel-adr-rhhby.html.

About Roche Holdings AG Basel

Roche Holding AG engages in the diagnostics and pharmaceuticals businesses in Switzerland, Germany, and rest of Europe. It offers pharmaceutical products for anaemia, anticoagulation therapy, bone, cancer, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, infectious diseases, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid disorders, liver, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus diseases.

Recommended Story: What strategies should day traders use to execute a trade?

Want to see what other hedge funds are holding RHHBY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roche Holdings AG Basel ADR (OTCMKTS:RHHBY).

Institutional Ownership by Quarter for Roche Holdings AG Basel (OTCMKTS:RHHBY)

Receive News & Ratings for Roche Holdings AG Basel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holdings AG Basel and related companies with MarketBeat.com's FREE daily email newsletter.